Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Lowman

Gastroenterology Columbia, SC Medical Doctor

NPI 1083617880 CMS profile 49324

3 Richland Medical Park Dr Ste 120, Columbia, SC 29203

Open in the dashboard

General payments

$7,522

413 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Lowman of Columbia, SC is reported in the CMS Open Payments database as having received $7,522 across 413 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75 2
2024 General $34 2
2023 General $1,079 69
2022 General $1,518 96
2021 General $2,160 152
2020 General $781 49
2019 General $1,875 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Lowman
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Anthony Lowman were reported at $75. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Anthony Lowman Gastroenterology median Middle half National median
2019 $1,875 $417 $126–$1,100 $163
2020 $781 $224 $74–$624 $114
2021 $2,160 $352 $106–$1,054 $132
2022 $1,518 $448 $129–$1,270 $149
2023 $1,079 $533 $150–$1,390 $160
2024 $34 $605 $160–$1,606 $164
2025 $75 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,871 138 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,092 70 payments
  3. Boston Scientific Corporation $941 9 payments
  4. Janssen Biotech, Inc. $491 29 payments
  5. Gilead Sciences, Inc. $439 25 payments
  6. Covidien LP $388 4 payments
  7. Celgene Corporation $315 19 payments
  8. QOL Medical, LLC $313 15 payments
  9. Pfizer Inc. $254 17 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $220 13 payments
  11. Other $1,198 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,452 408 payments
  2. Travel and Lodging $896 3 payments
  3. Education $175 2 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $874 55 payments
  2. SPYGLASS $699 5 payments
  3. LINZESS $566 51 payments
  4. MAVYRET $557 33 payments
  5. STELARA $491 29 payments
  6. CREON $450 40 payments
  7. HUMIRA $398 28 payments
  8. ZEPOSIA $337 20 payments
  9. XELJANZ $254 17 payments
  10. ZENPEP $200 14 payments
  11. Other $2,887 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

204

Median for Gastroenterology: 569

Drug cost

$126,761

Median for Gastroenterology: $104,976

Branded share of claims

50%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 13 $86,559
Creon Lipase/Protease/Amylase Brand 19 $37,259
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 50 $805
Pantoprazole Sodium Generic 37 $637
Esomeprazole Magnesium Generic 19 $623
Omeprazole Generic 35 $452
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 20 $301
Famotidine Generic 11 $124

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$4,326

Medicare's payments for the services billed

Medicare patients

25

Average age 69

Services billed

28

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 44%
Heart failure 0%
Atrial fibrillation 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

413 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record